Procept Biorobotics misses Q4 revenue, adjusted EBITDA estimates

PROCEPT BioRobotics

25/02/2026 21:20

Overview

Surgical robotics firm's Q4 revenue rose 12% yr/yr but missed analyst expectations

Adjusted EBITDA for Q4 missed estimates, showing a loss of $19 mln

Company achieved highest procedure volume to date, selling 65 new systems

Outlook

Company expects full-year 2026 revenue between $390 mln and $410 mln

Company forecasts full-year 2026 U.S. procedure growth of 39% to 48%

Company anticipates full-year 2026 gross margin of approximately 65%

Result Drivers

PROCEDURE VOLUME - Achieved highest procedure volume to date with approximately 12,200 procedures in Q4

COMMERCIAL REALIGNMENT - Realigned commercial organization and established a launch team to focus on durable procedure growth

PRICING STRATEGY - Implemented a disciplined handpiece pricing strategy, improving average selling price by 5%

Company press release: ID:nGNX5vRVj4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$76.38 mln
$94.14 mln (13 Analysts)
Q4 Net Income
-$29.85 mln
Q4 Adjusted EBITDA
Miss
-$19.01 mln
-$2.80 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Procept Biorobotics Corp is $51.00, about 87.1% above its February 24 closing price of $27.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)